Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dextroamphetamine sulfate
Drug ID BADD_D00637
Description Dextroamphetamine is the dextrorotary enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label].
Indications and Usage Used to treat attention deficit hyperactivity disorder (ADHD).
Marketing Status Prescription; Discontinued
ATC Code N06BA02
DrugBank ID DB01576
KEGG ID D02078
MeSH ID D003913
PubChem ID 5825
TTD Drug ID D0T3LF
NDC Product Code 24338-855; 0406-8958; 63629-2374; 24338-856; 75826-125; 0115-9927; 11534-188; 24338-852; 64896-674; 13107-036; 13107-035; 0406-8961; 45963-304; 43386-870; 43386-871; 51862-346; 0555-0952; 24338-853; 10702-065; 75826-121; 75826-120; 52536-510; 0115-9928; 52536-500; 24338-850; 51634-0222; 0115-9929; 11014-0322; 68382-944; 75826-126; 61960-0210; 51862-345; 11014-0323; 45963-303; 0406-8960; 51862-344; 0555-0953; 0406-8962; 52536-520; 64896-675; 68382-941; 0406-8959; 52536-530; 68382-942; 75826-124; 24338-851; 68382-943; 11534-189; 68382-945; 11014-0324; 45963-305; 10702-066; 66993-359; 49812-0058; 24338-854; 63629-2375; 21724-701; 75826-123; 75826-122; 0406-1950; 64896-673; 52536-515; 65392-0114
Synonyms Dextroamphetamine | Dexamphetamine | Dexamfetamine | dextro-Amphetamine | dextro Amphetamine | d-Amphetamine | d Amphetamine | Dexedrine | DextroStat | Oxydess | Curban | Dextroamphetamine Sulfate | Sulfate, Dextroamphetamine | Dextro-Amphetamine Sulfate | Dextro Amphetamine Sulfate | d-Amphetamine Sulfate | d Amphetamine Sulfate
Chemical Information
Molecular Formula C18H28N2O4S
CAS Registry Number 51-63-8
SMILES CC(CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N.OS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis cerebral24.05.02.008; 17.08.02.006; 10.02.02.014--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Cardiac death08.04.01.007; 02.03.04.015--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Growth retardation15.03.01.006--
Affect lability19.04.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Malnutrition14.03.02.004--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Psychotic disorder19.03.01.002--
Device stimulation issue27.01.02.005--Not Available
The 4th Page    First    Pre   4    Total 4 Pages